Carboxypeptidase B1: A novel, targetable contributor to thromboembolic complications in severe acute pancreatitis?

BACKGROUND: Severe acute pancreatitis (SAP) is associated with increased thrombotic risk. Systemic release of pancreatic proteases in SAP may alter susceptibility to endogenous fibrinolysis, but this remains unexplored. Pancreatic carboxypeptidase B1 (CPB1) is a protease activated by trypsin that shares cleavage specificity with thrombin-activatable fibrinolysis inhibitor, which cleaves C-terminal lysine residues off fibrin, impairing co-localization of tissue plasminogen activator (tPA) and plasminogen and rendering clots resistant to fibrinolysis. We hypothesized that circulating CPB1 would be elevated in SAP patients and contribute to fibrinolytic resistance. METHODS: Plasma and clinical data were prospectively collected from SAP patients (n=15), matched critically ill controls without pancreatitis (n=13), and healthy controls (n=4) with IRB approval and informed consent. CPB1 levels were measured through ELISA. Clot lysis assays assessed fibrinolysis in response to tPA. Healthy control plasma was tested with and without porcine pancreas CPB1 to assess the effect of CPB1 on fibrinolysis. Transition midpoints (TM's) were defined as the time to 50% clot lysis. Clinical data were analyzed using Mann-Whitney U and Fisher exact tests. Assay results were analyzed using Kruskall-Wallis test. Significance was set at P<0.05. RESULTS: Demographics were similar between groups. SAP patients had markedly elevated CPB1 levels (154.0 [58.4-388.0] ng/mL) compared with sick (7.0 [4.1-15.6] ng/mL, P<0.0001) and healthy controls (4.0 [2.1-4.4], P<0.001). Healthy control plasma supplemented with porcine pancreas CPB1 demonstrated complete disruption of fibrinolysis compared with healthy plasma without CPB1. SAP patients had the highest resistance to tPA-induced fibrinolysis, with significantly higher baseline TMs than critically ill controls (42.0 [21.7-126.6] vs. 22.8 [18.3-33.7], P=0.04). CONCLUSIONS: Patients with SAP have uniquely elevated circulating levels of CPB1, which may contribute to thromboembolism in SAP through fibrinolytic resistance. Further investigation into targeted CPB1 inhibition as a potential therapeutic strategy in SAP is warranted to potentially reduce development of organ failure and mortality. LEVEL OF EVIDENCE: N/A (Basic Science).

Authors

Institutions

Publication Details

Journal
The Journal of Trauma: Injury, Infection, and Critical Care
Published
2026-11-16
DOI
https://doi.org/10.1097/ta.0000000000005236
Primary Topic
Pancreatitis Pathology and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Carboxypeptidase B1: A novel, targetable contributor to thromboembolic complications in severe acute pancreatitis?

Christopher D. Barrett, Peter K. Moore, Flobater I. Gawargi, Elizabeth R. Maginot et al.
The Journal of Trauma: Injury, Infection, and Critical Care
Pancreatitis Pathology and Treatment
article

Carboxypeptidase B1: A novel, targetable contributor to thromboembolic complications in severe acute pancreatitis?

Christopher D. Barrett, Peter K. Moore, Flobater I. Gawargi, Elizabeth R. Maginot, Ali Aftabjahani, Nicolle K. Barmettler, Trace B Moody, Chengliang Wu, Ashely A. Clegg, Mohamed Hamed, Collin M. White, Paul Kim, Reynold Henry
article en

Abstract

BACKGROUND: Severe acute pancreatitis (SAP) is associated with increased thrombotic risk. Systemic release of pancreatic proteases in SAP may alter susceptibility to endogenous fibrinolysis, but this remains unexplored. Pancreatic carboxypeptidase B1 (CPB1) is a protease activated by trypsin that shares cleavage specificity with thrombin-activatable fibrinolysis inhibitor, which cleaves C-terminal lysine residues off fibrin, impairing co-localization of tissue plasminogen activator (tPA) and plasminogen and rendering clots resistant to fibrinolysis. We hypothesized that circulating CPB1 would be elevated in SAP patients and contribute to fibrinolytic resistance. METHODS: Plasma and clinical data were prospectively collected from SAP patients (n=15), matched critically ill controls without pancreatitis (n=13), and healthy controls (n=4) with IRB approval and informed consent. CPB1 levels were measured through ELISA. Clot lysis assays assessed fibrinolysis in response to tPA. Healthy control plasma was tested with and without porcine pancreas CPB1 to assess the effect of CPB1 on fibrinolysis. Transition midpoints (TM's) were defined as the time to 50% clot lysis. Clinical data were analyzed using Mann-Whitney U and Fisher exact tests. Assay results were analyzed using Kruskall-Wallis test. Significance was set at P<0.05. RESULTS: Demographics were similar between groups. SAP patients had markedly elevated CPB1 levels (154.0 [58.4-388.0] ng/mL) compared with sick (7.0 [4.1-15.6] ng/mL, P<0.0001) and healthy controls (4.0 [2.1-4.4], P<0.001). Healthy control plasma supplemented with porcine pancreas CPB1 demonstrated complete disruption of fibrinolysis compared with healthy plasma without CPB1. SAP patients had the highest resistance to tPA-induced fibrinolysis, with significantly higher baseline TMs than critically ill controls (42.0 [21.7-126.6] vs. 22.8 [18.3-33.7], P=0.04). CONCLUSIONS: Patients with SAP have uniquely elevated circulating levels of CPB1, which may contribute to thromboembolism in SAP through fibrinolytic resistance. Further investigation into targeted CPB1 inhibition as a potential therapeutic strategy in SAP is warranted to potentially reduce development of organ failure and mortality. LEVEL OF EVIDENCE: N/A (Basic Science).

The Journal of Trauma: Injury, Infection, and Critical Care
Nebraska Medical Center (US), Thrombosis and Atherosclerosis Research Institute (CA), University of Colorado Anschutz Medical Campus (US), University of Nebraska Medical Center (US), McMaster University (CA)
Good health and well-being
Pancreatitis Pathology and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon